CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 1 filers reported holding CHEMOCENTRYX INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $290,138,000 | +2349.2% | 5,616,301 | +1074.8% | 0.07% | +2133.3% |
| Q2 2022 | $11,846,000 | +22.4% | 478,069 | +23.9% | 0.00% | +50.0% |
| Q1 2022 | $9,677,000 | -50.5% | 385,983 | -28.2% | 0.00% | -50.0% |
| Q4 2021 | $19,563,000 | +283.2% | 537,291 | +80.0% | 0.00% | +300.0% |
| Q3 2021 | $5,105,000 | +52.0% | 298,541 | +19.0% | 0.00% | 0.0% |
| Q2 2021 | $3,358,000 | -89.5% | 250,806 | -59.7% | 0.00% | -87.5% |
| Q1 2021 | $31,867,000 | -32.4% | 621,926 | -18.3% | 0.01% | -33.3% |
| Q4 2020 | $47,155,000 | +78.6% | 761,547 | +58.1% | 0.01% | +71.4% |
| Q3 2020 | $26,404,000 | -21.1% | 481,822 | -17.2% | 0.01% | -30.0% |
| Q2 2020 | $33,464,000 | +260.7% | 581,585 | +151.9% | 0.01% | +233.3% |
| Q1 2020 | $9,278,000 | -17.7% | 230,905 | -19.0% | 0.00% | 0.0% |
| Q4 2019 | $11,278,000 | +2173.8% | 285,163 | +290.1% | 0.00% | – |
| Q3 2019 | $496,000 | -40.0% | 73,096 | -17.8% | 0.00% | – |
| Q2 2019 | $827,000 | -69.2% | 88,894 | -54.0% | 0.00% | -100.0% |
| Q1 2019 | $2,683,000 | +13.9% | 193,160 | -10.5% | 0.00% | 0.0% |
| Q4 2018 | $2,355,000 | -14.7% | 215,812 | -1.2% | 0.00% | 0.0% |
| Q3 2018 | $2,761,000 | -4.9% | 218,373 | -0.9% | 0.00% | 0.0% |
| Q2 2018 | $2,903,000 | +5.5% | 220,447 | +9.0% | 0.00% | 0.0% |
| Q1 2018 | $2,752,000 | +73.2% | 202,336 | -24.2% | 0.00% | – |
| Q4 2017 | $1,589,000 | -2.9% | 267,066 | +21.2% | 0.00% | – |
| Q3 2017 | $1,636,000 | +138.1% | 220,440 | +200.4% | 0.00% | – |
| Q2 2017 | $687,000 | +19.1% | 73,384 | -7.5% | 0.00% | – |
| Q1 2017 | $577,000 | +33.6% | 79,299 | +35.9% | 0.00% | – |
| Q4 2016 | $432,000 | +100.9% | 58,344 | +64.2% | 0.00% | – |
| Q3 2016 | $215,000 | -15.0% | 35,534 | -37.0% | 0.00% | – |
| Q2 2016 | $253,000 | +52.4% | 56,389 | -15.5% | 0.00% | – |
| Q1 2016 | $166,000 | +5.7% | 66,714 | +243.2% | 0.00% | – |
| Q4 2015 | $157,000 | +52.4% | 19,439 | +14.5% | 0.00% | – |
| Q3 2015 | $103,000 | -89.7% | 16,976 | -88.4% | 0.00% | – |
| Q4 2014 | $1,003,000 | +621.6% | 146,834 | +486.3% | 0.00% | – |
| Q3 2013 | $139,000 | – | 25,046 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |